ALLOX
eDR56Effective DR: 56/100. Below median. Measured by StartupHub.ai. Median 68.Trust63Data Trust: 63/100. Above median. Measured by StartupHub.ai. Median 61.ALLOX is a biotechnology company developing a drug discovery platform that combines high-throughput genetics, experimental biology, and artificial intelligence to identify previously unexplored opportunities for developing small-molecule therapeutics.
About
ALLOX is a Barcelona-based biotechnology company developing an experimental and AI-enabled platform for the systematic discovery of allosteric drug targets. By combining high-throughput genetics, computational biology, and drug discovery, ALLOX aims to identify functional sites in proteins that can unlock new therapeutic approaches for previously difficult-to-drug targets. The company's platform measures the effects of thousands of mutations in parallel, revealing allosteric, orthosteric, and other regulatory sites, including new potential binding pockets.
Similar companies
Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.
Shares Biotechnology, Oncology
Biotechnology company focused on cellular rejuvenation to reverse disease and extend healthspan.
Shares Biotechnology, Genomics
Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.
Shares Biotechnology, Drug Discovery
Epicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).
Shares Biotechnology, Biotech
A life sciences company that has developed a high-throughput platform for mapping molecular cell architecture at nanoscale resolution.
Shares Biotechnology, Genomics
Freenome is a biotechnology company developing a multi-cancer early detection blood test using machine learning and biology.
Shares Biotechnology, Healthcare
Key facts
- Website
- allox.bio
- Headquarters
- Barcelona, Spain
- Founded
- 2023
- Total funding
- $11M (Seed)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 29 Oct 2026 | Seed | $11M | Sabadell Asabys |
Tech stack
Detected on allox.bio, last scanned 29 Oct 2026. Run your own scan
- Frontend
- Next.js
- Analytics
- Google Tag Manager
- CDN
- Vercel
- Email provider
- Google Workspace
ALLOX scores 10. Does yours?
That is its Ahrefs DR: the backlink strength of a domain, on the Ahrefs 0 to 100 scale. Paste your website and you get yours in about a minute.
Frequently asked
What does ALLOX do?
This information can then be leveraged to design targeted small-molecule therapeutics against high-value targets that have historically proven difficult to drug, such as intracellular protein-protein interactions and transcription factors.
Is ALLOX trustworthy and reputable?
StartupHub's Data Trust & Reputation score for ALLOX is 63 out of 100, a generally safe rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has ALLOX raised?
ALLOX has raised a total of $11M in funding. The most recent round on record is Seed.
Public record
SEC filings, insider activity, nonprofit links and pay benchmarks for ALLOX
